Empowering Regulatory T Cells in Autoimmunity

Trends in Molecular Medicine

Volumn 22, Issue 9, 2016, Pages 784-797

  Kasper, Isaac R ^a   Apostolidis, Sokratis A ^a   Sharabi, Amir ^a,b   Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALDESLEUKIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DECITABINE; EVEROLIMUS; FINGOLIMOD; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PYRAZOLOPYRIMIDINE DERIVATIVE; RAPAMYCIN; STAT5B PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BACH2; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR HELIOS; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL LINEAGE; CELL METABOLISM; CHRONIC DIARRHEA; ECZEMA; EPIGENETICS; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; IPEX SYNDROME; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PROTEIN EXPRESSION; RECURRENT INFECTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; EPIGENESIS, GENETIC; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, REGULATORY;

EID: 84990966815     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.07.003     Document Type: Review

References (122)

1. 1 Nishizuka, Y., Sakakura, T., Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 166 (1969), 753–755.
2. 2 Malek, T.R., The biology of interleukin-2. Annu. Rev. Immunol. 26 (2008), 453–479.
3. 3 Suzuki, H., et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268 (1995), 1472–1476.
4. 4 Willerford, D.M., et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3 (1995), 521–530.
5. 5 Sakaguchi, S., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 (1995), 1151–1164.
6. 6 Josefowicz, S.Z., et al. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30 (2012), 531–564.
7. 7 Miyao, T., et al. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 36 (2012), 262–275.
8. 8 Allan, S.E., et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19 (2007), 345–354.
9. 9 Russell, W.L., et al. Exceptional inheritance of a sex-linked gene in the mouse explained on the basis that the X/O sex-chromosome constitution is female. Proc. Natl. Acad. Sci. U.S.A. 45 (1959), 554–560.
10. 10 Fontenot, J.D., et al. Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat. Immunol. 4 (2003), 330–336.
11. 11 Hori, S., et al. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003), 1057–1061.
12. 12 Bennett, C.L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27 (2001), 20–21.
13. 13 Powell, B.R., et al. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J. Pediatr. 100 (1982), 731–737.
14. 14 Wildin, R.S., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27 (2001), 18–20.
15. 15 Fontenot, J.D., et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6 (2005), 1142–1151.
16. 16 Barron, L., et al. Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J. Immunol. 185 (2010), 6426–6430.
17. 17 Malek, T.R., et al. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17 (2002), 167–178.
18. 18 Burchill, M.A., et al. Distinct effects of STAT5 activation on CD4 + and CD8 + T cell homeostasis: development of CD4 + CD25 + regulatory T cells versus CD8 + memory T cells. J. Immunol. 171 (2003), 5853–5864.
19. 19 Klatzmann, D., Abbas, A.K., The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15 (2015), 283–294.
20. 20 von Spee-Mayer, C., et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis., 2015, 10.1136/annrheumdis-2015-207776 Published online August 31, 2015.
21. 21 Liu, Y., et al. A critical function for TGF-[beta] signaling in the development of natural CD4 + CD25 + Foxp3 + regulatory T cells. Nat. Immunol. 9 (2008), 632–640.
22. 22 Li, M.O., Rudensky, A.Y., T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat. Rev. Immunol. 16 (2016), 220–233.
23. 23 Ouyang, W., et al. Transforming growth factor-β signaling curbs thymic negative selection promoting regulatory T cell development. Immunity 32 (2010), 642–653.
24. 24 Rao, S., et al. c-Rel is required for chromatin remodeling across the IL-2 gene promoter. J. Immunol. 170 (2003), 3724–3731.
25. 25 Zheng, Y., et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463 (2010), 808–812.
26. 26 Feng, Y., et al. A mechanism for expansion of regulatory T-cell repertoire and its role in self-tolerance. Nature 528 (2015), 132–136.
27. 27 Yurchenko, E., et al. Inflammation-driven reprogramming of CD4 + Foxp3 + regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS ONE, 7, 2012, e35572.
28. 28 Duarte, J.H., et al. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur. J. Immunol. 39 (2009), 948–955.
29. 29 Komatsu, N., et al. Heterogeneity of natural Foxp3 + T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 1903–1908.
30. 30 Zhou, X., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10 (2009), 1000–1007.
31. 31 Hori, S., Lineage stability and phenotypic plasticity of Foxp3(+) regulatory T cells. Immunol. Rev. 259 (2014), 159–172.
32. 32 Burchill, M.A., et al. Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity 28 (2008), 112–121.
33. 33 Feng, Y., et al. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell 158 (2014), 749–763.
34. 34 Li, X., et al. Function of a Foxp3 cis-element in protecting regulatory T cell identity. Cell 158 (2014), 734–748.
35. 35 Rubtsov, Y.P., et al. Stability of the regulatory T cell lineage in vivo. Science 329 (2010), 1667–1671.
36. 36 Floess, S., et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol., 5, 2007, e38.
37. 37 Wang, L., et al. Foxp3 + T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity. Blood 121 (2013), 3631–3639.
38. 38 Nair, V.S., Oh, K.I., Down-regulation of Tet2 prevents TSDR demethylation in IL2 deficient regulatory T cells. Biochem. Biophys. Res. Commun. 450 (2014), 918–924.
39. 39 DuPage, M., et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity 42 (2015), 227–238.
40. 40 Morikawa, H., et al. Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 5289–5294.
41. 41 van Loosdregt, J., et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 39 (2013), 259–271.
42. 42 Chen, Z., et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity 39 (2013), 272–285.
43. 43 Zhao, Y., et al. E3 ubiquitin ligase Cbl-b regulates thymic-derived CD4 + CD25 + regulatory T cell development by targeting Foxp3 for ubiquitination. J. Immunol. 194 (2015), 1639–1645.
44. 44 Samstein, R.M., et al. Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. Cell 151 (2012), 153–166.
45. 45 Ouyang, W., et al. Novel Foxo1-dependent transcriptional programs control T(reg) cell function. Nature 491 (2012), 554–559.
46. 46 Roychoudhuri, R., et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature 498 (2013), 506–510.
47. 47 Kim, E.H., et al. Bach2 regulates homeostasis of Foxp3 + regulatory T cells and protects against fatal lung disease in mice. J. Immunol. 192 (2014), 985–995.
48. 48 Thornton, A.M., et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3 + T regulatory cells. J. Immunol. 184 (2010), 3433–3441.
49. 49 Kim, H.J., et al. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science 350 (2015), 334–339.
50. 50 Nakagawa, H., et al. Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), 6248–6253.
51. 51 Takatori, H., et al. Helios enhances Treg cell function in cooperation with FoxP3. Arthritis Rheumatol. 67 (2015), 1491–1502.
52. 52 Spence, A., et al. Targeting Treg signaling for the treatment of autoimmune diseases. Curr. Opin. Immunol. 37 (2015), 11–20.
53. 53 Perl, A., Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat. Rev. Rheumatol. 12 (2016), 169–182.
54. 54 Delgoffe, G.M., et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12 (2011), 295–303.
55. 55 Coe, D.J., et al. Metabolic regulation of regulatory T cell development and function. Front. Immunol., 5, 2014, 590.
56. 56 Michalek, R.D., et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4 + T cell subsets. J. Immunol. 186 (2011), 3299–3303.
57. 57 Zeng, H., et al. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature 499 (2013), 485–490.
58. 58 Powell, J.D., et al. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 30 (2012), 39–68.
59. 59 Walsh, P.T., et al. PTEN inhibits IL-2 receptor-mediated expansion of CD4 + CD25 + Tregs. J. Clin. Invest. 116 (2006), 2521–2531.
60. 60 Delgoffe, G.M., et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501 (2013), 252–256.
61. 61 Shrestha, S., et al. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat. Immunol. 16 (2015), 178–187.
62. 62 Huynh, A., et al. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat. Immunol. 16 (2015), 188–196.
63. 63 Apostolidis, S.A., et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat. Immunol. 17 (2016), 556–564.
64. 64 Charbonnier, L.M., et al. Control of peripheral tolerance by regulatory T cell-intrinsic Notch signaling. Nat. Immunol. 16 (2015), 1162–1173.
65. 65 Beyer, M., et al. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat. Immunol. 12 (2011), 898–907.
66. 66 Kondo, M., et al. SATB1 plays a critical role in establishment of immune tolerance. J. Immunol. 196 (2016), 563–572.
67. 67 Torgerson, T.R., Ochs, H.D., Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J. Allergy Clin. Immunol. 120 (2007), 744–750 quiz 751–742.
68. 68 Gambineri, E., et al. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J. Allergy Clin. Immunol. 122 (2008), 1105–1112.
69. 69 Kucuk, Z.Y., et al. A challenging undertaking: stem cell transplantation for immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. J. Allergy Clin. Immunol. 137 (2016), 953–955.
70. 70 Sharfe, N., et al. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc. Natl. Acad. Sci. U.S.A. 94 (1997), 3168–3171.
71. 71 Caudy, A.A., et al. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J. Allergy Clin. Immunol. 119 (2007), 482–487.
72. 72 Bernasconi, A., et al. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics 118 (2006), e1584–e1592.
73. 73 Nadeau, K., et al. STAT5b deficiency: an unsuspected cause of growth failure, immunodeficiency, and severe pulmonary disease. J. Pediatr. 158 (2011), 701–708.
74. 74 Tivol, E.A., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995), 541–547.
75. 75 Schubert, D., et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat. Med. 20 (2014), 1410–1416.
76. 76 Charbonnier, L.M., et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J. Allergy Clin. Immunol. 135 (2015), 217–227.
77. 77 Lo, B., et al. Autoimmune Disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349 (2015), 436–440.
78. 78 Ohl, K., Tenbrock, K., Regulatory T cells in systemic lupus erythematosus. Eur. J. Immunol. 45 (2015), 344–355.
79. 79 Lyssuk, E.Y., et al. Reduced number and function of CD4 + CD25highFoxP3 + regulatory T cells in patients with systemic lupus erythematosus. Adv. Exp. Med. Biol. 601 (2007), 113–119.
80. 80 Bonelli, M., et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int. Immunol. 20 (2008), 861–868.
81. 81 Chowdary Venigalla, R.K., et al. Reduced CD4 + ,CD25 − T cell sensitivity to the suppressive function of CD4 + ,CD25high,CD127 − /low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 58 (2008), 2120–2130.
82. 82 Afeltra, A., et al. The involvement of T regulatory lymphocytes in a cohort of lupus nephritis patients: a pilot study. Intern. Emerg. Med. 10 (2015), 677–683.
83. 83 Daniel, C., et al. Enhancement of antigen-specific Treg vaccination in vivo. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 16246–16251.
84. 84 Battaglia, M., et al. Rapamycin selectively expands CD4 + CD25 + FoxP3 + regulatory T cells. Blood 105 (2005), 4743–4748.
85. 85 Link, W., et al. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J. Biol. Chem. 284 (2009), 28392–28400.
86. 86 Liu, G., et al. The S1P1-mTOR axis directs the reciprocal differentiation of TH1 and Treg cells. Nat. Immunol. 11 (2010), 1047–1056.
87. 87 Liu, G., et al. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat. Immunol. 10 (2009), 769–777.
88. 88 Lai, Z.W., et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 64 (2012), 2937–2946.
89. 89 Yin, Y., et al. Normalization of CD4 + T cell metabolism reverses lupus. Sci. Transl. Med., 7, 2015, 274ra218.
90. 90 Koga, T., et al. KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3(+) regulatory T cells in MRL/lpr mice. Autoimmunity 47 (2014), 445–450.
91. 91 Ichinose, K., et al. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum. 63 (2011), 523–529.
92. 92 Koga, T., et al. CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. The Journal of Clinical Investigation 124 (2014), 2234–2245.
93. 93 Fujikawa, K., et al. Calcium/calmodulin-dependent protein kinase II (CaMKII) regulates tumour necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells (FLS) by phosphorylation of Akt. Clin. Exp. Rheumatol. 27 (2009), 952–957.
94. 94 Westra, J., et al. Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. BMC Musculoskelet. Disord. 11 (2010), 1–11.
95. 95 Benjamin, D., et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10 (2011), 868–880.
96. 96 Polansky, J.K., et al. DNA methylation controls Foxp3 gene expression. Eur. J. Immunol. 38 (2008), 1654–1663.
97. 97 Josefowicz, S.Z., et al. Cutting edge: TCR stimulation is sufficient for induction of Foxp3 expression in the absence of DNA methyltransferase 1. J. Immunol. 182 (2009), 6648–6652.
98. 98 Hancock, W.W., et al. HDAC inhibitor therapy in autoimmunity and transplantation. Ann. Rheum. Dis. 71:Suppl. 2 (2012), i46–i54.
99. 99 Regna, N.L., et al. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin. Immunol. 162 (2016), 58–73.
100. 100 Mizui, M., et al. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J. Immunol. 193 (2014), 2168–2177.
101. 101 Humrich, J.Y., et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann. Rheum. Dis. 74 (2015), 791–792.
102. 102 Saadoun, D., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365 (2011), 2067–2077.
103. 103 Koreth, J., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365 (2011), 2055–2066.
104. 104 von Spee-Mayer, C., et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 75 (2015), 1407–1415.
105. 105 Bruyn, G.A., et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Ann. Rheum. Dis. 67 (2008), 1090–1095.
106. 106 Yap, D.Y., et al. Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Nephrology (Carlton) 17 (2012), 676–680.
107. 107 Ando, S., et al. FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. Biochem. Biophys. Res. Commun. 394 (2010), 804–810.
108. 108 Han, Y., et al. FTY720 abrogates collagen-induced arthritis by hindering dendritic cell migration to local lymph nodes. J. Immunol. 195 (2015), 4126–4135.
109. 109 La Mantia, L., et al. Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev, 4, 2016, CD009371.
110. 110 Lee, J., et al. A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model. Int. J. Rheum. Dis. 18 (2015), 514–523.
111. 111 Chen, W., et al. Conversion of peripheral CD4 + CD25- naive T cells to CD4 + CD25 + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198 (2003), 1875–1886.
112. 112 Khattri, R., et al. An essential role for Scurfin in CD4 + CD25 + T regulatory cells. Nat. Immunol. 4 (2003), 337–342.
113. 113 Hsieh, C.S., et al. An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. Nat. Immunol. 7 (2006), 401–410.
114. 114 Li, X., Zheng, Y., Regulatory T cell identity: formation and maintenance. Trends Immunol. 36 (2015), 344–353.
115. 115 Chaudhry, A., et al. CD4 + regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326 (2009), 986–991.
116. 116 Zheng, Y., et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458 (2009), 351–356.
117. 117 Koch, M.A., et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 10 (2009), 595–602.
118. 118 Wang, Y., et al. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity 35 (2011), 337–348.
119. 119 Cipolletta, D., Adipose tissue-resident regulatory T cells: phenotypic specialization, functions and therapeutic potential. Immunology 142 (2014), 517–525.
120. 120 Arpaia, N., et al. A distinct function of regulatory T cells in tissue protection. Cell 162 (2015), 1078–1089.
121. 121 Wei, J., et al. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis. Nat. Immunol. 17 (2016), 277–285.
122. 122 Kabat, A.M., et al. The autophagy gene Atg16l1 differentially regulates Treg and TH2 cells to control intestinal inflammation. Elife, 5, 2016, e12444.